Tirzepatide / Retatrutide Blend

This vial pairs 30 mg of tirzepatide with 30 mg of retatrutide, two incretin agonists that vendors sell together as GLP-2 / GLP-3.

Community-reportedFixed-ratio blend reference

Also known as: Tirzepatide and Retatrutide

Open the calculator

Blend calculations, explained

A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.

Per-component concentration math

Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.

Vial strength is not a target amount

Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.

How to read the dosing on this page

Blend-level rows

Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.

Component rows

Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.

One draw, every component

The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.

Molecular profile of each component

Tirzepatide / Retatrutide Blend is 2 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.

Tirzepatide30 mg per vial

Formula
C225H348N48O68
Molar mass
4,813 g/mol
Amino acids
39
Sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20 diacid-gamma-Glu-AEEA-AEEA)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Class
Synthetic lipidated 39-residue peptide built on the GIP sequence, with two Aib residues, a C-terminal amide and a C20 fatty diacid attached through gamma-glutamate and two AEEA linkers to lysine 20; GIP and GLP-1 receptor dual agonist

PubChem CID 156588324Tirzepatide page

Retatrutide30 mg per vial

Formula
C221H342N46O68
Molar mass
4,731 g/mol
CAS number
2381089-83-2
Amino acids
39
Sequence
Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(alpha-Me-Leu)-Leu-Asp-Lys-Lys(C20 diacid-gamma-Glu-AEEA)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Class
Synthetic lipidated 39-residue peptide; GIP, GLP-1 and glucagon receptor triple agonist

PubChem CID 171390338Retatrutide page

Reported protocols for Tirzepatide / Retatrutide Blend

What published studies and recent community write-ups report about amounts, timing and course length. 2 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.

ContextDoseFrequencyRouteCourseSource
Community-reported2 rows
Community reports of running the two drugs together5 mg of retatrutide with 5 mg of tirzepatide per week is one reported lower-dose pairing; other reports use full doses of eachOnce weeklySubcutaneousNot defined; some reports describe the combination feeling redundant after 4-8 weeksNot describedCommunity resource2026
This May 2026 analysis states plainly that no published trial has tested co-administration of tirzepatide and retatrutide and that the combination is theorised entirely from single-drug data. It reads the pharmacology as more retatrutide rather than a new mechanism, because both drugs act on the GIP and GLP-1 receptors and only retatrutide adds glucagon receptor activity, and it lists stronger appetite suppression, a heavier gastrointestinal burden and additive resting heart rate increases as the recurring community reports. Those reports come from forums and podcasts, with selection bias and under-reporting of adverse effects, and the page describes them as hypothesis-generating rather than data.
Stacking instead of switching: the reported ratioA full retatrutide dose plus a low, unspecified tirzepatide dose; the page's retatrutide figures are 0.25-0.5 mg weekly rising to 1.5-4 mg over 8-12 weeks in community use, against 2-12 mg in the trialsOnce weekly, with retatrutide sometimes split into two or three injectionsSubcutaneousNot stated for the combination; the page gives 4-5 weeks at a fixed dose for retatrutide to reach steady stateNot applicableCommunity resource2026
This August 2026 article says reported stacking ratios cluster around a full retatrutide dose with a small tirzepatide dose, the stated rationale being that retatrutide supplies the glucagon-driven metabolic effect while a little tirzepatide holds appetite down. It calls the addition mechanistically redundant, since retatrutide already acts on both receptors tirzepatide targets, notes that gastrointestinal events are dose-related for both drugs, and states that no clinical trial has evaluated the combination and no safety data exist for it. A fixed 1:1 vial cannot deliver the lopsided ratio these reports describe.
Sources for this section (8)
  1. ZEPBOUND (tirzepatide) injection: Prescribing InformationDailyMed, National Library of Medicine2026Clinical

Plus 7 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.

Reported protocols by component

What sources report for each peptide on its own. In Tirzepatide / Retatrutide Blend the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.

Tirzepatide

  • ClinicalFDA label, Zepbound (weight management and obstructive sleep apnea)
    Reported amount
    2.5 mg to start; maintenance 5, 10 or 15 mg (weight), 10 or 15 mg (OSA); 15 mg maximum
    Frequency
    Once weekly, increasing by 2.5 mg after at least 4 weeks on the current dose
    Route
    Subcutaneous, abdomen, thigh or upper arm, rotating sites; single-dose pens or vials (0.5 mL) and a multi-dose KwikPen
    Course
    Continuous; 2.5 mg is for initiation only and is not an approved maintenance dose
    DailyMed, National Library of Medicine, 2026
  • Community-reportedTelehealth compounding chart (10 and 20 mg/mL kits)
    Reported amount
    2.5 mg (25 units at 10 mg/mL; 12.5 units at 20 mg/mL) rising to 15 mg (75 units at 20 mg/mL)
    Frequency
    Once weekly, 4 weeks per step
    Route
    Subcutaneous from compounded vials, pre-mixed or reconstituted with bacteriostatic water, using a U-100 insulin syringe
    Course
    Same ladder as the label: 2.5, 5, 7.5, 10, 12.5, 15 mg
    Community resource, 2026
  • ClinicalFDA label, Mounjaro (type 2 diabetes)
    Reported amount
    2.5 mg for 4 weeks, then 5 mg; further 2.5 mg steps as needed; 15 mg maximum in adults, 10 mg in children
    Frequency
    Once weekly, at any time of day, with or without food
    Route
    Subcutaneous, abdomen or thigh, or the back of the upper arm when injected by someone else
    Course
    Continuous
    DailyMed, National Library of Medicine, 2026
10 more rows on the Tirzepatide page

Retatrutide

  • ClinicalPhase 2 obesity trial
    Reported amount
    1, 4, 8 or 12 mg maintenance (initial dose 2 or 4 mg)
    Frequency
    Once weekly
    Route
    Subcutaneous
    Course
    48 weeks, then a 4-week safety follow-up
    New England Journal of Medicine (PubMed), 2023
  • Community-reportedSlow community ramp
    Reported amount
    0.5 mg start, rising to 8 mg (some to 12 mg)
    Frequency
    Once weekly, stepping up every 4 weeks
    Route
    Subcutaneous
    Course
    About 20 weeks of escalation, then open-ended maintenance
    Community resource, 2026
  • ClinicalPhase 2 type 2 diabetes trial
    Reported amount
    0.5, 4, 8 or 12 mg maintenance (escalated from 2 or 4 mg every 4 weeks)
    Frequency
    Once weekly
    Route
    Subcutaneous
    Course
    36 weeks
    The Lancet (PubMed), 2023
6 more rows on the Retatrutide page

What is available now

These fields come from the existing picker, blend catalog and observed presentation data. They are identity and availability context, not evidence of effectiveness.

This vial pairs 30 mg of tirzepatide with 30 mg of retatrutide, two incretin agonists that vendors sell together as GLP-2 / GLP-3. No study of any kind has tested the two drugs together: tirzepatide is a GIP/GLP-1 dual agonist and retatrutide a GIP/GLP-1/glucagon triple agonist, so stacking them doubles up on the same two receptors, and the Zepbound label states that coadministration of tirzepatide with any GLP-1 receptor agonist is not recommended. The evidence for each drug lives on its component page; the vendor listings found for this pair sell 20 mg of retatrutide with 40 mg of tirzepatide or do not state the split, so the 30 / 30 ratio here should be checked against the label and certificate of analysis of the vial in hand.

  • 1

    Entry type

    Fixed-ratio blend reference

    Kept separate from single-peptide evidence and terminology.

  • 2

    Evidence status

    Structured review queued

    No evidence level is assigned until references and study models are reviewed.

  • 3

    Calculator access

    Advanced Blend workspace

    Calculator access performs arithmetic; it does not establish an amount or protocol.

  • 4

    Market presentation data

    No reviewed observation on file

    The vial label remains the authoritative source for any calculation.

Recorded blend variants

Each number is the vial amount for that component. It is not a per-draw amount.

30 / 30 mg
Tirzepatide
30 mg
Retatrutide
30 mg

Sources

3 curated references, each with its journal, year and study model, plus 7 community resources reported but not linked.

  1. Tirzepatide (PubChem CID 156588324)PubChem, National Library of Medicine2026Not graded
  2. Retatrutide (PubChem CID 171390338)PubChem, National Library of Medicine2026Not graded
  3. ZEPBOUND (tirzepatide) injection: Prescribing InformationDailyMed, National Library of Medicine2026Human

Guides that go deeper